> top > docs > PubMed:32471903 > annotations

PubMed:32471903 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-OGER-BB

Id Subject Object Predicate Lexical cue
T1 52-60 SP_7 denotes COVID-19
T2 64-70 NCBITaxon:9606 denotes people
T3 109-117 SP_7 denotes COVID-19
T4 180-196 SP_7 denotes CTIVES: COVID-19
T5 209-215 NCBITaxon:9606 denotes people
T6 338-346 SP_7 denotes COVID-19
T7 373-379 NCBITaxon:9606 denotes people
T8 428-439 NCBITaxon:1 denotes individuals
T9 467-475 SP_7 denotes COVID-19
T10 485-493 SP_7 denotes COVID-19
T11 940-944 GO:0016265 denotes died
T12 980-990 CHEBI:8382 denotes prednisone
T13 980-990 CHEBI:8382 denotes prednisone
T14 1128-1146 CHEBI:35842 denotes antirheumatic drug
T15 1128-1146 CHEBI:35842 denotes antirheumatic drug
T16 1207-1217 CHEBI:66921 denotes inhibitors
T17 1207-1217 CHEBI:66921 denotes inhibitors
T18 1337-1373 CHEBI:35475 denotes Non-steroidal anti-inflammatory drug
T19 1337-1373 CHEBI:35475 denotes Non-steroidal anti-inflammatory drug
T20 1375-1380 CHEBI:35472 denotes NSAID
T21 1375-1380 CHEBI:35472 denotes NSAID
T22 1488-1497 CHEBI:35222 denotes inhibitor
T23 1488-1497 CHEBI:35222 denotes inhibitor
T24 1504-1507 PR:000000134 denotes TNF
T25 1625-1637 CHEBI:35718 denotes antimalarial
T26 1625-1637 CHEBI:35718 denotes antimalarial
T27 1714-1728 CHEBI:24261 denotes glucocorticoid
T28 1714-1728 CHEBI:24261 denotes glucocorticoid
T29 1813-1816 PR:000000134 denotes TNF
T30 1925-1931 CHEBI:35472 denotes NSAIDs
T31 1925-1931 CHEBI:35472 denotes NSAIDs

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-175 Sentence denotes Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
T2 176-265 Sentence denotes OBJECTIVES: COVID-19 outcomes in people with rheumatic diseases remain poorly understood.
T3 266-403 Sentence denotes The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease.
T4 404-412 Sentence denotes METHODS:
T5 413-532 Sentence denotes Case series of individuals with rheumatic disease and COVID-19 from the COVID-19 Global Rheumatology Alliance registry:
T6 533-564 Sentence denotes 24 March 2020 to 20 April 2020.
T7 565-655 Sentence denotes Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation.
T8 656-810 Sentence denotes Age, sex, smoking status, rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analysed.
T9 811-819 Sentence denotes RESULTS:
T10 820-873 Sentence denotes A total of 600 cases from 40 countries were included.
T11 874-945 Sentence denotes Nearly half of the cases were hospitalised (277, 46%) and 55 (9%) died.
T12 946-1089 Sentence denotes In multivariable-adjusted models, prednisone dose ≥10 mg/day was associated with higher odds of hospitalisation (OR 2.05, 95% CI 1.06 to 3.96).
T13 1090-1336 Sentence denotes Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively).
T14 1337-1464 Sentence denotes Non-steroidal anti-inflammatory drug (NSAID) use was not associated with hospitalisation status (OR 0.64, 95% CI 0.39 to 1.06).
T15 1465-1686 Sentence denotes Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed.
T16 1687-1699 Sentence denotes CONCLUSIONS:
T17 1700-1893 Sentence denotes We found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with rheumatic disease.
T18 1894-1987 Sentence denotes Neither exposure to DMARDs nor NSAIDs were associated with increased odds of hospitalisation.
T1 0-175 Sentence denotes Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
T2 176-265 Sentence denotes OBJECTIVES: COVID-19 outcomes in people with rheumatic diseases remain poorly understood.
T3 266-403 Sentence denotes The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease.
T4 404-412 Sentence denotes METHODS:
T5 413-532 Sentence denotes Case series of individuals with rheumatic disease and COVID-19 from the COVID-19 Global Rheumatology Alliance registry:
T6 533-564 Sentence denotes 24 March 2020 to 20 April 2020.
T7 565-655 Sentence denotes Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation.
T8 656-810 Sentence denotes Age, sex, smoking status, rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analysed.
T9 811-819 Sentence denotes RESULTS:
T10 820-873 Sentence denotes A total of 600 cases from 40 countries were included.
T11 874-945 Sentence denotes Nearly half of the cases were hospitalised (277, 46%) and 55 (9%) died.
T12 946-1089 Sentence denotes In multivariable-adjusted models, prednisone dose ≥10 mg/day was associated with higher odds of hospitalisation (OR 2.05, 95% CI 1.06 to 3.96).
T13 1090-1336 Sentence denotes Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively).
T14 1337-1464 Sentence denotes Non-steroidal anti-inflammatory drug (NSAID) use was not associated with hospitalisation status (OR 0.64, 95% CI 0.39 to 1.06).
T15 1465-1686 Sentence denotes Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed.
T16 1687-1699 Sentence denotes CONCLUSIONS:
T17 1700-1893 Sentence denotes We found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with rheumatic disease.
T18 1894-1987 Sentence denotes Neither exposure to DMARDs nor NSAIDs were associated with increased odds of hospitalisation.

hydroxychloroquine

Id Subject Object Predicate Lexical cue hp_id
T1 1465-1471 Phenotype denotes Tumour http://purl.obolibrary.org/obo/HP_0002664